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Abstract
Purpose This study was aimed to determine whether structured written and verbal education provided to patients by community
pharmacists about high blood pressure (BP) and its treatment would be (a) better retained and (b) be associated with improved BP
control as compared to patients receiving verbal advice only.
Methods The study was designed as a randomised controlled trial and was conducted in the West Midlands, UK, between
January 2014 and June 2014. The primary outcome measures were differences in systolic and diastolic BP from baseline and
retention of information about high BP assessed with a questionnaire at 2-, 4- and 26-week follow-up points.
Results A total of 64 adults were included in the study. At the week 26 follow-up, compared to participants in the control group,
there was a significant improvement in the knowledge of intervention participants about the risks associated with high BP (p <
0.001) and awareness about potential adverse effects of the new BP medicine (p < 0.001). Similarly, there was a greater and more
significant reduction in systolic BP in favour of the intervention group 8 mmHg (95% CI 2.1–13.3 p = 0.009) compared to
6 mmHg (95%CI 0.6–11.7 p = 0.02) in the control group at the week 4 follow-up. However, this greater effect of an intervention
on BP was not sustained at the 26-week follow-up. For diastolic BP, there was no added effect of the intervention.
Conclusion This randomised controlled trial suggests that although written advice provided by community pharmacists in
comparison to verbal advice was more effective in improving knowledge and understanding of patients about hypertension
and its treatment, it did not lead to better blood pressure control.
Keywords Community pharmacists . Education . Hypertension . Randomised controlled trial
Introduction
It has been reported that behavioural interventions—patient-
centred counselling, self-monitoring of blood pressure (BP)
and structured training courses—on BP management lead to
better BP control in patients with hypertension as compared to
patients receiving ordinary care [1]. Pooled results from this
systematic review that included 15 studies involving 4072
patients reported that patient-centred counselling led to a re-
duction of 11.1 mmHg in systolic and 3.2 mmHg reduction in
diastolic BP [1]. The review did not specify if the patient-
centred counselling was written or verbal. Similar findings
were reported in a cluster randomised controlled study in the
USA [2]. Patients receiving multifactorial interventions in-
cluding written patient education experienced a reduction of
8 mmHg in systolic BP and achieved a better BP control. Lack
of adequate knowledge about high BP has been reported as a
barrier to medication adherence by hypertensive patients [3].
In the UK, the NewMedicines Service (NMS) allows com-
munity pharmacists to explain medicine use to patients with
long-term medical conditions such as hypertension. Within
this scheme, the advice is structured but verbal, with no spe-
cific written information provided on drugs or the disease
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being treated. There is limited evidence to suggest that provi-
sion of written medical advice to patients about a disease and
its treatment is better retained by patients than verbal informa-
tion [4] and leads to better clinical outcomes [2]. The study
aimed to determine whether the structured information pro-
vided to patients verbally and in writing by community phar-
macists about high BP will be associated with improved BP
control and be better retained by patients.
Methods
This study was a 6-month multicentre randomised controlled
trial (RCT) conducted across four community pharmacies in
the West Midlands area of the UK between January 2014 and
June 2014. The trial was registered on ClinicalTrials.gov
(Identifier NCT01939860). Participants in both groups were
required to attend four visits in total over a period of 6 months
(at week 0, 2, 4 and 26).
Study participants and procedures
All participants 18 years or over, male or female and had been
started on a BPmedication were eligible for the study. Eligible
participants were identified by a member of the pharmacy
team. Exclusion criteria included patients under 18 years and
patients not capable of giving written consent.
The questionnaire drawn from a 12-item questionnaire de-
veloped by the National Institutes of Health [5] was aimed to
explore participants’ basic knowledge of BP including aware-
ness about the risks associated with high BP and knowledge
about the participants’ new BP medicine. Face validity of the
questionnaire was undertaken by seeking feedback from a
pharmacists advisory group including six pharmacists as well
as from an expert hypertension advisory group based in the
West Midlands area. Besides, the questionnaire was also
piloted on a group of 20 patients that included patients attend-
ing the BP Clinic at a large teaching hospital in the West
Midlands and patients attending one of the participating phar-
macies in Birmingham. Based on the feedback obtained dur-
ing pilot work, the wording of some of the questions of the
questionnaire was edited to make the questions simpler and
easier to understand. The final questionnaire had a Flesch-
Kincaid reading grade level of 5.8 [6].
Three readings of systolic and diastolic BP were recorded
for both intervention and control groups participants during all
four visits (weeks 0, 2, 4 and 26). BP was recorded electron-
ically by trained pharmacy staff using a British Hypertension
Society (BHS)-approved Omron BP monitor [7]. As per the
BHS guidelines, the final two readings of both systolic and
diastolic BP were used to calculate the average readings.
Intervention and comparator (usual care)
Participants in both groupswere asked to continue to take their
prescribed anti-hypertensive medications during the study. In
addition to usual care, participants in the intervention group
received individually tailored information sheets containing
structured advice on BP and their anti-hypertensive medica-
tion that was prepared using National Institute for Health and
Care Excellence (NICE) guidance CG 127 [8]. These infor-
mation sheets were provided by a trained pharmacist during
three face to face sessions (week 0, 2 and 4) over a period of
6 months. All participating pharmacists were provided 30-min
training by the chief investigator of the study. Besides, training
was provided to pharmacy staff on measuring blood pressure.
Pharmacists were specifically instructed not to provide any
help with answering the questions as the same questionnaire
was used during all four visits. However, pharmacists were
allowed to assist the participants in understanding the medical
terminologies used in the questions when needed. The partic-
ipants in the control group received a separate information
sheet containing information on the NMS in addition to usual
care.
Data management and analysis
The sample size calculation indicated that a sample size of 54
per group completing the study will provide a power of 80% at
the 5% level in a two-tailed test to detect a reduction of a size
equal to 0.6 standard deviations (SD) in systolic and diastolic
BP. The primary outcome of the study was to detect the dif-
ference in systolic and diastolic BP from baseline. The sec-
ondary outcome was the retention of information about BP
assessed with a questionnaire at 2, 4 and 26 weeks follow-
up. ANOVA was used to calculate the mean difference in
systolic and diastolic BP (in mmHg). Cross tabulation was
used to analyse the responses to hypertension knowledge
questions.
Results
A total of 64 participants were included in the study (see Fig. 1
for flow of participants through the study). At baseline, no
statistically significant differences were found in the demo-
graphics of intervention and the control group participants
(see Table 1 for participant demographics).
Impact on systolic and diastolic BP
At the end of week 4 follow-up, there was a greater reduction
in systolic BP in favour of the intervention group 8 mmHg
(95% CI 2.1–13.3 p = 0.009) compared to 6 mmHg (95% CI
0.6–11.7 p = 0.02) in the control group. However, this greater
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effect of intervention on systolic BP was not sustained at the
26-week follow-up with little difference remaining between
the groups, 8 mmHg (95% CI 2.1–13.3 p = 0.01) intervention
group vs. 7 mmHg (95% confidence interval 0.6–11.7 p =
0.02) control group. For diastolic BP, there was no added
effect of the intervention and both groups achieved a similar
reduction in diastolic BP at the 26-week follow-up, 4.5 mmHg
(95% CI 1.2–7.7 p = 0.008) intervention group vs. 5 mmHg
(95% CI 1.3–8.8 p = 0.009).
Knowledge about hypertension and its treatment
With regard to the assessment of knowledge about BP, there
was a significant improvement in the knowledge of interven-
tion participants in comparison to participants in the control
group at the 26-week follow-up including knowledge about
the risks associated with high blood pressure (p < 0.001), the
role of lifestyle measures in reducing high blood pressure (p <
0.01) and awareness about potential adverse effects of the new
blood pressure medicine (p < 0.001) (see Table 2 for
percentages of participants correctly answering each
hypertension knowledge question).
26 participants declined 
to participate 
18 Lack of time 
6 distance to pharmacy 
2 Non-English 
speaking  
90 participants screened for 
eligibility 
64 participants agreed to 
participate and 
randomised 
31 participants 
randomised to 
intervention group 
(A) 
33 participants 
randomised to control 
group (B) 
25 participants 
complete the study (6 
withdrawals) 
31 participants 
complete the study (2 
withdrawals) 
Fig. 1 Flow of participants
through the study
Table 1 Participant demographics at Baseline. BMI—bodymass index.
All data are given in numbers (percentages) unless otherwise indicated
Variables Intervention Control
Mean age years (SD) 64.7 (10.5) 60.0 (9.3)
Gender
Male 14 (45%) 18 (55%)
Female 17 (55%) 15 (45%)
Ethnicity
White Caucasian 24 (78%) 25 (76%)
South Asian 5 (16%) 6 (18%)
African Caribbean 2 (6%) 2 (6%)
Mean BMI kg/m2 (SD) 29.0 (5.9) 30.3 (5.2)
Systolic blood pressure mmHg (SD) 142 (17.0) 143 (16.9)
Diastolic blood pressure mmHg (SD) 79 (11.4) 83 (12.9)
Other medical conditions (self-reported) 6 (19%) 7 (21%)
Diabetes 1(3%) 0
Heart failure 1 (3%) 1 (3%)
Kidney disease 1 (3%) 4 (13%)
Heart attack 1 (3%) 1 (3%)
Stroke 21 (67%) 20 (60%)
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Discussion
The findings of this study suggest that although there was a
greater reduction in systolic BP in favour of the intervention
group compared to control group at the 4-week follow-up, this
greater effect of intervention on BP was not sustained at the
26-week follow-up with both groups achieving similar reduc-
tion in BP. These findings suggest that verbal advice provided
by pharmacists alone was equally effective as the written ad-
vice in supporting a reduction in systolic and diastolic BP of
hypertensive patients following the introduction of a new BP-
lowering medicine. However, compared to verbal advice only,
provision of structured verbal and written education was
associated with an improvement sustained over 6 months in
the knowledge of hypertension.
There can be many possible reasons for the non-
sustainability of greater BP control initially achieved by inter-
vention participants over the long-term follow-up. It is not
completely clear if the intervention participants initially
responded better to their new BP treatment than the control
participants. Another reason for the loss of their greater BP
control could be that perhaps they needed frequent reminders
about high BP and its treatment. A recent study that included
1300 adults with high BP compared two intervention groups
who received education about high BP and its treatment
through text message reminders and interactive text
Table 2 Percentages of participants correctly answering each hypertension knowledge question
Intervention
(n = 25)
Control
(n = 31)
Difference between groups
expressed by p value+
Knowledge
question
Baseline Follow-up Difference
within group
p value*
Baseline Follow-up Difference
within group
p value*
Baseline Follow-up
Top blood pressure number
should be under 140?
16 (64%) 24 (96%) p = 0.01 18 (58%) 23 (74%) p = 0.25 p = 0.65 p = 0.02
Lower blood number
should be under 90?
15 (60%) 24 (96%) p = 0.02 21 (68%) 24 (77%) p = 0.85 p = 0.54 p = 0.04
Hypertension is a
lifelong disease?
11 (44%) 25 (100%) p < 0.001 20 (65%) 25 (84%) p = 0.29 p = 0.12 p = 0.02
Hypertension can cause
heart attacks?
11 (44%) 25 (100%) p < 0.001 20 (65%) 25 (84%) p = 0.51 p = 0.99 p = 0.19
Hypertension can cause
strokes?
21 (84%) 25 (100%) p = 0.03 26 (84%) 29 (94%) p = 0.09 p = 0.47 p = 0.36
Hypertension can cause
kidney disease?
21 (84%) 25 (100%) p = 0.20 21 (68%) 25 (80%) p = 0.30 p = 0.87 p = 0.36
Hypertension does not
cause asthma?
14 (56%) 23 (92%) p = 0.03 18 (58%) 22 (71%) p = 0.20 p = 0.68 p = 0.12
Hypertension does not
cause cancer?
12 (48%) 19 (76%) p = 0.02 13 (42%) 18 (58%) p = 0.18 p = 0.87 p = 0.14
Losing weight reduces
high blood pressure?
15 (60%) 23 (92%) p = 0.005 12 (39%) 16 (52%) p = 0.39 p = 0.04 p = 0.41
Cutting salt reduces high
blood pressure?
20 (80%) 24 (96%) p = 0.004 26 (84%) 29 (94%) p = 0.44 p = 0.70 p = 0.25
Cutting alcohol reduces
high blood pressure?
19 (76%) 25 (100%) p = 0.18 28 (90%) 30 (97%) p = 0.65 p = 0.27 p = 0.41
Anti-hypertensive should
be taken daily?
19 (76%) 25 (100%) p = 0.002 28 (90%) 30 (97%) p = 0.79 p = 0.04 p = 0.19
Anti-hypertensive should
be taken long-term?
22 (88%) 25 (100%) p = 0.45 28 (90%) 28 (90%) p = 0.34 p = 0.27 p = 0.11
Name of your new blood
pressure medicine?
20 (80%) 25 (100%) p = 0.01 28 (90%) 28 (90%) p = 0.35 p = 0.96 p = 0.43
Dose of your new blood
pressure medicine?
16 (64%) 20 (80%) p = 0.08 20 (65%) 22 (71%) p = 0.81 p = 0.81 p = 0.25
How your new blood
pressure medicine
works?
17 (68%) 21 (84%) p = 0.09 22 (71%) 22 (71%) p = 0.03 p = 0.07 p = 0.01
Awareness about
adverse effects?
6 (24%) 21 (84%) p < 0.001 7 (23%) 11 (35%) p = 0.21 p = 0.90 p < 0.001
Incidence of adverse
effects?
10 (40%) 5 (20%) p = 0.12 8 (26%) 6 (19%) p = 0.55 p = 0.39 p = 1.00
*Chi-square test at p < 0.05. p value* indicates the difference within the study groups and p value+ indicates the difference between the study groups
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messaging to a control group receiving standard care. The
study reported that those who had received text messages
had a slightly greater reduction in their BP and were more
likely to have achieved a controlled BP [9].
This study has several limitations. Although, the study re-
ported a greater initial reduction in systolic BP of intervention
participants compared to control group, such initial better blood
pressure control could have been explained by the risk of con-
founding factors including the type and dose of antihyperten-
sives used, and degree of patient compliance with their medi-
cation. Such confounders could have been addressed by appro-
priate matching of controls. In addition, we were not able to
recruit the initially planned number of participants, resulting in
reduced power for assessment of the outcome measures. This
was primarily due to the withdrawal of two participating phar-
macies from the study. Finally, owing to the nature of pharma-
cists’ interventions in this study, participants and the investiga-
tors could not be blinded to the study intervention.
The initial reduction in BP by pharmacist-led interventions
has important implications for primary and secondary preven-
tion of cardiovascular morbidity and mortality. For example,
evidence from a meta-analysis reported that even a 2-mmHg
reduction in systolic BP could reduce the risk of stroke by
10% in the USA [10]. Another analysis suggests that a
sustained 2-mmHg reduction in diastolic BP would be expect-
ed to result in a 6% reduction in the risk of coronary heart
disease and 15% decrease in stroke [11]. However, since few-
er participants were recruited in the study than required, find-
ings of this study should therefore be interpreted with caution.
Future studies with adequate sample size would be required to
assess the effectiveness and sustainability of pharmacist-led
interventions in the long term in clinical practice.
Conclusion
This randomised controlled trial suggests that althoughwritten
advice provided by community pharmacists in comparison to
verbal advice was more effective in improving knowledge and
understanding of patients about hypertension and its treat-
ment, it did not lead to better blood pressure control.
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